Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(PBIO, USEG, CRWE.OB, AVNR) Stock Report from

|Includes: Avanir Pharmaceuticals, Inc (AVNR), PBIO, USEG





AVANIR Pharmaceuticals, Inc. (Nasdaq:AVNR) is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need.

AVNR reported that the U.S. Food and Drug Administration (FDA) has approved NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate) capsules, as the first treatment for pseudobulbar affect.

NUEDEXTA is indicated for the treatment of pseudobulbar affect, which occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying.

Pseudobulbar affect (NYSE:PBA) episodes typically occur out of proportion or incongruent to the patient's underlying emotional state.

These patients frequently experience embarrassment due to their unpredictable emotional outbursts, leading to disruption of their interpersonal relationships and social isolation.

NUEDEXTA™ is the first and only FDA-approved treatment for pseudobulbar affect (PBA). NUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations.

This FDA approval represents a significant step forward for people who live with the debilitating effects of PBA.

More about AVNR at


crwe black CRWE, Crown Equity Holdings Inc., CRWE.OB

CRWE is a consulting organization which provides and assists small business owners with the knowledge required in taking their company public, and has re-focused its primary vision with its aligned group of independent website divisions to providing media advertising services, as a worldwide online media advertising publisher, dedicated to the distribution of quality branding information, as well as search engine optimization for its clients.

CRWE reported in June of this year its 1- 10 forward stock split, as well as in August announcing that CRWE had surpassed One Million dollars (1,000,000) in sales (this compares to $232,510 for the three quarters ending September 30, 2009 and $ 659,907 total sales for the year 2009).

CRWE is utilizing today’s technology to advertise, promote and market public companies globally.

CRWE’s proprietary network technology allows their publishing department to get their content to millions of readers daily across the world.

CRWEis expanding its business by opening another office in Pakistan. publishes financial content to all the major countries and covers all the accredited stock exchanges. The goal for 2010 is to have all CRWE’s clients’ press releases, articles and news content published in every major financial country’s native language.

More about CRWE at


Pressure BioSciences, Inc. (Nasdaq:PBIO) has been awarded a Therapeutic Discovery Grant ("TDG") for $244,479.25.

The TDG Program is part of the Patient Protection and Affordable Care Act of 2010 signed into law on March 23, 2010. Grant funds are not taxable for federal income tax purposes, do not require performance of any additional studies or services, and are immediately available to the Company.


U.S. Energy Corp. (Nasdaq:USEG) plans on issuing a press release to report selected highlights and financial results after filing its second quarter 10-Q on Monday, November 8, 2010.


Signup for FREE Daily Stock Alerts From


Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.